ASLAN Pharmaceuticals (ASLN) Scheduled to Post Quarterly Earnings on Friday

ASLAN Pharmaceuticals (NASDAQ:ASLN) is scheduled to be announcing its earnings results on Friday, April 26th.

ASLAN Pharmaceuticals (NASDAQ:ASLN) last announced its quarterly earnings results on Friday, April 12th. The company reported ($0.78) earnings per share for the quarter. On average, analysts expect ASLAN Pharmaceuticals to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

ASLAN Pharmaceuticals Stock Performance

Shares of ASLN stock opened at $0.47 on Thursday. The stock has a 50 day moving average of $0.61 and a 200 day moving average of $0.72. The stock has a market cap of $7.68 million, a P/E ratio of -0.17 and a beta of 1.45. ASLAN Pharmaceuticals has a twelve month low of $0.39 and a twelve month high of $4.69.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ASLN. Piper Sandler reiterated an “overweight” rating and set a $10.00 price target (down from $15.00) on shares of ASLAN Pharmaceuticals in a research report on Wednesday, March 13th. HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of ASLAN Pharmaceuticals in a report on Tuesday.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.